J. J. Starling

A. Dantzig, J. J. Starling, S. Pratt, 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

C. Shih, B. Norman, A. Dantzig, 1997, Advances in enzyme regulation.

High yield, site-specific coupling of N-terminally modified beta-lactamase to a proteolytically derived single-sulfhydryl murine Fab'.

K. Rose, R. Offord, J. J. Starling, 1994, Bioconjugate chemistry.

A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer

D. Meyer, J. J. Starling, T. Shepherd, 1991 .

Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of Gemcitabine, LY2334737, in Human Tumor Xenografts

A. Dantzig, R. Shepard, G. Donoho, 2013, Molecular Cancer Therapeutics.

Gemcitabine , LY 2334737 , in Human Tumor Xenografts Efficacy of Low-Dose Oral Metronomic Dosing of the Prodrug of

A. Dantzig, R. Shepard, G. Donoho, 2013 .

Low-DoseOralMetronomicDosingof theProdrug of Gemcitabine , LY 2334737 , in Human Tumor Xenografts

A. Dantzig, R. Shepard, G. Donoho, 2013 .

Development of a dual label fluorescence technique that can be utilized to elucidate the mechanism of action of monoclonal antibody-drug conjugates.

J. J. Starling, J. Corvalan, P. Marder, 1988, Cancer research.

Disulfide bonding of a human prostate tumor-associated membrane antigen recognized by monoclonal antibody D83.21.

G. Wright, J. J. Starling, 1985, Cancer research.

Immunohistochemical Localization of Prostate Carcinoma-associated Antigens1

P. Schellhammer, George L. Wright, J. J. Starling, 2006 .

Immunohistochemical localization of prostate carcinoma-associated antigens.

P. Schellhammer, G. Wright, J. J. Starling, 1983, Cancer research.

Tissue distribution and cellular location of the antigens recognized by human monoclonal antibodies 16.88 and 28A32.

R. Cote, M. Borowitz, J. J. Starling, 1988, Cancer research.

Monoclonal Antibodies to Human Prostate and Bladder Tumor-associated Antigens1

P. Schellhammer, George L. Wright, J. J. Starling, 2006 .

Metabolism of 2‐deoxy‐d‐galactose results in the accumulation of 2‐deoxy‐d‐galactose 1‐phosphate in brain 1

D. Keppler, J. J. Starling, D. O. R. Keppler, 1977, Journal of neurochemistry.

Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.

G. Stephenson, J. Bao, A. Dantzig, 2009, Journal of medicinal chemistry.

Nonclinical Assessment of Carcinogenic Risk and Tumor Growth Enhancement Potential of Prasugrel, a Platelet-Inhibiting Therapeutic Agent

A. Sanbuissho, P. Iversen, L. Buckley, 2012, International journal of toxicology.

Cyclohexyl-linked tricyclic isoxazoles are potent and selective modulators of the multidrug resistance protein (MRP1).

B. Norman, D. Paul, A. Dantzig, 2005, Bioorganic & medicinal chemistry letters.

Novel trityl linked drug immunoconjugates for cancer therapy

J. J. Starling, V. Patel, J. N. Hardin, 1995 .

A statistical evaluation of the binding of ferritin-conjugated lectins to the surface of rat cells. Topographical variations as a function of lectin concentration and cell type.

J. J. Starling, E. Walborg, D. Hixson, 1979, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

A microquantitative method to characterize lectin-induced cytoagglutination.

J. J. Starling, E. Walborg, E. Davis, 1976, Experimental cell research.

Monoclonal antibodies to human prostate and bladder tumor-associated antigens.

P. Schellhammer, George L. Wright, G. Wright, 1982, Cancer research.

Surface properties of normal and neoplastic rat liver cells. Lectin-induced cytoagglutination and lectin receptor activity of cell-surface glycopeptides.

J. J. Starling, E. Walborg, S. Capetillo, 1977, Experimental cell research.

The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation

T. Burke, R. Beckmann, Sheng-Bin Peng, 2013, Molecular Cancer Therapeutics.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Human prostate tissue antigens defined by murine monoclonal antibodies.

P. Schellhammer, G. Wright, J. J. Starling, 1986, Cancer research.

Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.

Shih-Hsun Chen, S. Wong, G. Plowman, 2016, Cancer discovery.

Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities.

S. Binkley, J. Gillespie, S. Wrighton, 1999, The Journal of pharmacology and experimental therapeutics.

Small Molecule Therapeutics Characterization of LY 2228820 Dimesylate , a Potent and Selective Inhibitor of p 38 MAPK with Antitumor Activity

R. Campbell, J. Velasco, J. Graff, 2014 .

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

R. Campbell, J. Velasco, J. Graff, 2011, Molecular Cancer Therapeutics.

Characterization of LY 2228820 dimesylate , a potent and selective inhibitor of p 38 MAPK with anti-tumor activity

R. Campbell, J. Velasco, J. Graff, 2013 .

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015, Cancer cell.

Inhibition of RAF Isoforms and Active Dimers by LY 3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers Graphical

Xiwen Ma, Shih-Hsun Chen, G. Plowman, 2015 .

Selective cloning of hybridoma cells for enhanced immunoglobulin production using flow cytometric cell sorting and automated laser nephelometry.

J. J. Starling, R. Baker, R. Fouts, 1990, Cytometry.

Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model

Tao Wei, Hui-Rong Qian, J. Yingling, 2008, BMC Genomics.

Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1).

B. Norman, D. Paul, M. M. Wagner, 2002, Bioorganic & medicinal chemistry letters.

Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma*

S. Estrem, Jiangang Liu, Sheng-Bin Peng, 2012, The Journal of Biological Chemistry.

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

H L Pearce, M. Sporn, N. Suh, 2001, Cancer research.

Monoclonal antibodies against a soluble cytoplasmic antigen in human prostatic epithelial cells

J. J. Starling, D. J. Merchant, S. M. Clarke, 1982, The Prostate.

A small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitro

J. Yingling, R. Foreman, M. Uhlik, 2006 .

Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.

J. J. Starling, V. Patel, J. Zimmermann, 1996, Bioconjugate chemistry.

A very early induction of major vault protein accompanied by increased drug resistance in U‐937 cells

L. Rome, V. Devanarayan, A. Stephen, 2002, International journal of cancer.

Production of monoclonal antibodies against a cell surface concanavalin A binding glycoprotein.

P. Klein, J. J. Starling, K. D. Noonan, 1979, Journal of supramolecular structure.

Surface properties of adult rat hepatocytes. Mechanism of increased concanavalin A-induced agglutinability following papain digestion.

J. J. Starling, E. Walborg, D. Hixson, 1977, Experimental cell research.

A novel CDK9 inhibitor shows potent anti-tumor efficacy in preclinical hematological tumor models

R. Gaynor, X. Ye, J. J. Starling, 2014 .

Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.

N. Suh, J. J. Starling, A. Palkowitz, 2001, Cancer research.

Dextran modification of a Fab'--beta-lactamase conjugate modulated by variable pretreatment of Fab' with amine-blocking reagents.

J. J. Starling, S. Mikolajczyk, M. Hagan, 1996, Bioconjugate chemistry.

Antiprostate carcinoma monoclonal antibody (D83.21) cross reacts with a membrane antigen expressed on cytomegalovirus‐transformed human fibroblasts

George L. Wright, A. Campbell, J. J. Starling, 1985, The Prostate.

Human prostate tissue antigens defined by murine monoclonal antibodies.

P. Schellhammer, G. Wright, J. J. Starling, 1986, Cancer research.

In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.

J. J. Starling, J. Strnad, T. Bumol, 1990, Cancer research.